Galera to present at 2022 american society for radiation oncology (astro) annual meeting

Malvern, pa., sept. 26, 2022 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its phase 3 roman trial of avasopasem for severe oral mucositis (som) and final data from its phase 2 aesop trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 american society for radiation oncology (astro) annual meeting, taking place october 23-26, 2022 in san antonio, texas. additionally, poster presentations will highlight the phase 2 eusom trial of avasopasem for som in europe and the ongoing greco-1 trial of rucosopasem for non-small cell lung cancer.
GRTX Ratings Summary
GRTX Quant Ranking